Why Annexin Pharmaceuticals stock moves
Annexin Pharmaceuticals rose, against a falling market.
Written after the close on ·
Why today
16,415 news analyzed todayAnnexin Pharmaceuticals rose, against a falling market.
Over the last five trading days the share rose very sharply while the OMX Stockholm 30 was roughly flat.
Trading volume was well above its usual level, a sign of heavy activity.
The move was very large for this stock, about six times a normal day.
Today's move of +11.53% was 5.5 times a normal day's 2.1%. OMX Stockholm 30 moved −1.01% on the same day.
Annexin Pharmaceuticals +11.53%OMX Stockholm 30 −1.01%Against the market
What analysts expect, and how often they have been right
Analysts’ estimates for Annexin Pharmaceuticals.
Price targets
Latest price 8.90 SEK
Has the share price followed the business?
Price and earnings moved in the same direction: 2 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −53% and earnings per share went from -10.94 SEK to -5.50 SEK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.m SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capm SEK
Price and earnings moved in the same direction: 2 out of 3 years.Market cap (Now): 77.6 m SEKRevenue 2025: 0.0 m SEK
What the key figures say about Annexin Pharmaceuticals
The figures connect what Annexin Pharmaceuticals earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -23.40 SEK–-5.50 SEK. Peers: Active Biotech -1.70 SEK, Strategic Partners 31.00 DKK, Initiator Pharma -0.60 SEK.
What the company sold during the year.
2022–2025: 0.0 m SEK–0.0 m SEK. Peers: Strategic Partners 0.3 m DKK. 2026 estimate: 0.0 m SEK (0.0 m SEK–0.0 m SEK). 2027 estimate: 48.5 m SEK (48.5 m SEK–48.5 m SEK).
Profit as a percentage of shareholders’ money in the company.
2022–2025: −366.5%–−135.1%. Peers: Active Biotech −140.6%, Strategic Partners 7.2%, Initiator Pharma −336.2%.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 4.86–17.08. Peers: Active Biotech 1.71, Strategic Partners 1.26.
Cash left after investments, divided by the number of shares.
2022–2025: -14.53 SEK–-5.17 SEK. Peers: Active Biotech -1.23 SEK, Strategic Partners -39.47 DKK, Initiator Pharma -0.34 DKK.
The percentage of assets financed by shareholders’ equity.
2022–2025: 70.3%–82.7%.
What to watch next, and why
The earnings report shows how Annexin Pharmaceuticals's revenue and profit have changed.
- Earnings report
The earnings report shows how Annexin Pharmaceuticals's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 16 report days Annexin Pharmaceuticals usually moved about 3.2%. On a normal day it moves 2.1%.
−6.46% Why? +3.12% −3.97% −5.52%
10,000 SEK in Annexin Pharmaceuticals bought on April 19, 2017 is worth 280 SEK today, with dividends reinvested.
The same amount in OMX Stockholm 30 with dividends would have become 27,000 SEK.
What would 10,000 SEK in Annexin Pharmaceuticals be worth today? →
What would 10,000 SEK in Annexin Pharmaceuticals be worth today?
280 SEK
with dividends reinvested, bought on April 19, 2017. The same amount in OMX Stockholm 30 with dividends would have become 27,000 SEK.
At worst it was worth 197 SEK (November 3, 2026).
The five biggest days of the journey
· +70.2% · the whole market rose 0.7% the same day
· −42.9% · the whole market rose 0.4% the same day
· −40.4% · the whole market fell 0.8% the same day
· +37.6% · the whole market fell 1.6% the same day
· +35.5% · the whole market fell 0.5% the same day
Earlier days
+34.04% market −0.11% Annexin Pharmaceuticals rose very sharply over the last five trading days, while the broader Stockholm market stayed roughly flat. Read →
Annexin Pharmaceuticals rose very sharply over the last five trading days, while the broader Stockholm market stayed roughly flat.
The move was very big for this stock, rare in the past year.
+26.27% market −0.32% Annexin Pharmaceuticals rose, moving against a slightly weaker market. Read →
Annexin Pharmaceuticals rose, moving against a slightly weaker market.
Over the last session OMX Stockholm 30 fell slightly, while Annexin Pharmaceuticals rose very sharply, so it clearly moved apart from the market.
Its move was very big for it, and trading was well above its usual level.
Earlier, on Thursday 22 October, the company presented its third-quarter report, which says its cash is expected to last until the end of February 2027.
+0.96% market +0.83% Annexin Pharmaceuticals rose, in line with the market. Read →
Annexin Pharmaceuticals rose, in line with the market.
The market's OMX Stockholm 30 rose clearly over the same day, so the stock tracked the broader rise.
Over the last five trading days the stock fell sharply, while the market rose slightly.
That fall is a big move for this stock, and it is near its lowest close of the past year.
−4.86% market −0.08% Annexin Pharmaceuticals fell, moving against a flat market. Read →
Annexin Pharmaceuticals fell, moving against a flat market.
Annexin Pharmaceuticals fell sharply in the last session, while OMX Stockholm 30 was roughly flat, so the stock moved against a calm market.
Over the last five trading days it fell very sharply, while the market rose slightly.
That is a very big move for this stock, about four times its normal five-day swing, and moves that large happened only about four times in the past year.
Its latest close sits at its lowest point of the past year.
−0.90% market +0.48% Annexin Pharmaceuticals slipped slightly, against a market rise. Read →
Annexin Pharmaceuticals slipped slightly, against a market rise.
Over the same day the OMX Stockholm 30 rose slightly, so the stock moved against the market.
The move was an ordinary one, within its usual daily range.
Over the last five trading days the stock fell sharply while the market rose clearly.
That weakness likely reflects wider selling in Nasdaq First North Sweden healthcare stocks, which fell about 4% over the same days.
−14.21% market +3.01% Annexin Pharmaceuticals fell sharply over the week, moving against a rising market. Read →
Annexin Pharmaceuticals fell sharply over the week, moving against a rising market.
Its share price was near its lowest level of the past year by the end of the week.
The company completed enrolment in its NEXUS study, its clinical trial, on 22 October, but the news did not explain the fall.
The company's third-quarter report, published 22 October, showed a larger loss and cash expected to last only until late February 2027, which likely weighed on the shares.
−3.74% market +0.41% Annexin Pharmaceuticals fell clearly without a company-news explanation. Read →
Annexin Pharmaceuticals fell clearly without a company-news explanation.
Over the last five trading days, Annexin Pharmaceuticals fell sharply, while the OMX Stockholm 30 rose sharply, so it lagged the market.
The fall was a very big move for this stock, roughly three times its usual five-day swing.
The shares are at their lowest close of the past year, well below the highest close of early November last year.
Company news from the week before, including its Q3 report and a trial enrollment update, does not clearly explain the fall.
−6.95% market +0.33% Annexin Pharmaceuticals fell sharply without a company-news explanation. Read →
Annexin Pharmaceuticals fell sharply without a company-news explanation.
Over the same days OMX Stockholm 30 rose slightly, so the stock moved against the market.
Over the last five trading days the shares fell very sharply, roughly four times a normal five-day move.
Trading volume was well above its usual level, about double a normal session.
The latest close sits at the lowest level of the past year.
−4.44% market −3.67% Annexin Pharmaceuticals edged lower over the past week, moving in line with a sharply weaker broader market. Read →
Annexin Pharmaceuticals edged lower over the past week, moving in line with a sharply weaker broader market.
The move was ordinary in size and trading was quiet.
The company published its third-quarter report and said cash should last until late February 2027, a funding concern that weighs on investor sentiment.
It also completed patient enrollment in its NEXUS study, a clinical trial of its drug candidate, with results expected at the end of the first quarter 2027.
−6.46% market −2.51% Annexin fell sharply after its quarterly report. Read →
Annexin fell sharply after its quarterly report.
Annexin Pharmaceuticals fell sharply in the last session, which was the trading day when its third-quarter report came out.
The market's main index, OMX Stockholm 30, also fell sharply that day, so the drop was not unusual against the market.
The report showed a loss for the quarter and cash that is expected to last until the end of February 2027.
Over the last five trading days the shares were roughly unchanged, while the market fell clearly.
Learn more · Why do stocks go up and down?